

CHARSIRE Biotechnology Corp.
 4F-1, No. 13, Nanke 2nd Rd., Xinshi Dist., Tainan City, Taiwan

REPORT NO : FA/2017/42165
Date : 2017/04/18



The following sample(s) was/were submitted and identified by/on behalf of client as:

Type of Product : Glycine max(L.) Merr. Extract
Sample condition : Please refer to the photos for sample shown at the last page of this report
Item No. : —
Lot. No. : GM101-C2-170401
Applicant : CHARISRE Biotechnology Corp.
Manufacture Date : —
Expiry Date : —
Date of Sample Received : 2017/04/12
Date of Testing : 2017/04/13
Test Requested : Determination of the pesticides
Test Method : With reference to AOAC Official Method 2007.01:Pesticide Residues in Foods by Acetonitrile Extraction and Partitioning with Magnesium Sulfate. Analysis were performed by GC/MS/MS and LC/MS/MS.

Test Results : **The sample was tested for 426 pesticides. and the results were found to be non-detected with those 426 pesticides as listed.**

- Note : 1. The test report merely reflects the test results of the consigned matters of the client and is not a certification of the legitimacy of the related products.
 2. The report is in vain if it is partly reproduced or used.
 3. The test result over LOQ is summarized in the table. All test items and LOQ are listed in appendix.
 4. If the testing item belongs to quantitative analysis then this column describes Limit of Quantification(LOQ).
 5. There are 310 testing items shown in the appendix which refer to MOHW Food No. 1031900615 Method of Test for Pesticide Residues in Food-Multi-Residue Analysis(5).

- END -



Link to SGS safety information platform
 Contact person : Sonny Ren, Ph.D.



This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Appendix

REPORT NO: FA/2017/42165

Date : 2017/04/18



Test items & LOQ List :

unit : ppm(mg/kg)

NO.	Test Item	CAS NO.	LOQ	NO.	Test Item	CAS NO.	LOQ
1.	2,3,5,6-Tetrachloroaniline	3481-20-7	0.05	41.	β-BHC	319-85-7	0.01
2.	2,4,5-T	93-76-5	0.02	42.	δ-BHC	319-86-8	0.01
3.	3-keto Carbofuran	16709-30-1	0.01	43.	Bifenazate	149877-41-8	0.01
4.	3-OH carbofuran	16655-82-6	0.01	44.	Bifenoxy	42576-02-3	0.01
5.	Abamectin	71751-41-2	0.01	45.	Bifenthrin	82657-04-3	0.01
6.	Acephate	30560-19-1	0.01	46.	s-Bioallethrin	28434-00-6	0.1
7.	Acequinocyl	57960-19-7	0.05	47.	Bioresmethrin	28434-01-7	0.05
8.	Acetamiprid	135410-20-7	0.01	48.	Bitertanol	55179-31-2	0.01
9.	Acetochlor	34256-82-1	0.01	49.	Boscalid	188425-85-6	0.01
10.	Acibenzolar-S-methyl	135158-54-2	0.02	50.	Bromacil	314-40-9	0.01
11.	Acifluorfen	50594-66-6	0.02	51.	Bromobutide	74712-19-9	0.05
12.	Acrinathrin	101007-06-1	0.01	52.	Bromophos-ethyl	4824-78-6	0.01
13.	Alachlor	15972-60-8	0.01	53.	Bromophos-methyl	2104-96-3	0.01
14.	Alanycarb	83130-01-2	0.02	54.	Bromopropylate	18181-80-1	0.01
15.	Aldicarb	116-06-3	0.01	55.	Bromuconazole	116255-48-2	0.01
16.	Aldicarb sulfone	1646-88-4	0.01	56.	Bupirimate	41483-43-6	0.01
17.	Aldicarb sulfoxide	1646-87-3	0.01	57.	Buprofezin	69327-76-0	0.01
18.	Aldrin	309-00-2	0.01	58.	Butachlor	23184-66-9	0.01
19.	Allethrin	584-79-2	0.02	59.	Butocarboxim	34681-10-2	0.01
20.	Alloxydim(sodium)	55635-13-7	0.01	60.	Butralin	33629-47-9	0.01
21.	Alphacypermethrin	67375-30-8	0.01	61.	Cadusafos	95465-99-9	0.05
22.	Ametryn	834-12-8	0.01	62.	Carbaryl	63-25-2	0.01
23.	Amisulbrom	348635-87-0	0.01	63.	Carbendazim	10605-21-7	0.01
24.	Amitraz	33089-61-1	0.02	64.	Carbofuran	1563-66-2	0.01
25.	Aramite	140-57-8	0.05	65.	Carbophenothion	786-19-6	0.01
26.	Asulam	3337-71-1	0.02	66.	Carbosulfan	55285-14-8	0.01
27.	Atrazine	1912-24-9	0.01	67.	Carboxin	5234-68-4	0.05
28.	Azaconazole	60207-31-0	0.05	68.	Carfentrazone-ethyl	128639-02-1	0.05
29.	Azimsulfuron	120162-55-2	0.02	69.	Carpropamid	104030-54-8	0.01
30.	Azinphos-methyl	86-50-0	0.01	70.	Chinomethionat	2439-01-2	0.01
31.	Azoxystrobin	131860-33-8	0.01	71.	Chlorantraniliprole	500008-45-7	0.01
32.	Benalaxyl	71626-11-4	0.01	72.	Chlorbenside	103-17-3	0.05
33.	Bendiocarb	22781-23-3	0.01	73.	Chlorbufam	1967-16-4	0.02
34.	Benfluralin	1861-40-1	0.01	74.	cis-Chlordane	5103-71-9	0.01
35.	Benfuracarb	82560-54-1	0.01	75.	trans-Chlordane	5103-74-2	0.01
36.	Benoxacor	98730-04-2	0.05	76.	Chlorfenapyr	122453-73-0	0.01
37.	Bensulfuron-methyl	83055-99-6	0.01	77.	Chlorfenson	80-33-1	0.05
38.	Bentazone	25057-89-0	0.01	78.	Chlorfenvinphos	470-90-6	0.05
39.	Benthiazole	21564-17-0	0.01	79.	Chlorfluzaron	71422-67-8	0.01
40.	α-BHC	319-84-6	0.01	80.	Chlormequat	999-81-5	0.1

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Appendix

REPORT NO: FA/2017/42165

Date : 2017/04/18



Test items & LOQ List :

unit : ppm(mg/kg)

NO.	Test Item	CAS NO.	LOQ	NO.	Test Item	CAS NO.	LOQ
81.	Chloropropylate	5836-10-2	0.01	121.	Deltamethrin	52918-63-5	0.01
82.	Chlorothalonil	1897-45-6	0.02	122.	Demeton-S-methyl	919-86-8	0.01
83.	Chloroxuron	1982-47-4	0.02	123.	Diafenthiuron	80060-09-9	0.02
84.	Chlorpropham	101-21-3	0.01	124.	Di-allate	2303-16-4	0.05
85.	Chlorpyrifos	2921-88-2	0.01	125.	Diazinon	333-41-5	0.01
86.	Chlorpyrifos-methyl	5598-13-0	0.01	126.	Dichlofenthion	97-17-6	0.05
87.	Chlorthal-dimethyl	1861-32-1	0.01	127.	Dichlormid	37764-25-3	0.05
88.	Chlorthiophos	60238-56-4	0.05	128.	Dichlorprop	120-36-5	0.02
89.	Chlozolinate	84332-86-5	0.01	129.	Dichlorvos	62-73-7	0.01
90.	Chromafenozide	143807-66-3	0.01	130.	Diclofop-methyl	51338-27-3	0.05
91.	Cinidon-ethyl	142891-20-1	0.02	131.	Di-clomezine	62865-36-5	0.02
92.	Cinosulfuron	94593-91-6	0.01	132.	Dicloran	99-30-9	0.01
93.	Clethodim	99129-21-2	0.02	133.	Dicofol&DCBP	115-32-2	0.01
94.	Clofentezine	74115-24-5	0.01	134.	Dicrotophos	141-66-2	0.01
95.	Clomazone	81777-89-1	0.01	135.	Dieldrin	60-57-1	0.01
96.	Clomeprop	84496-56-0	0.01	136.	Diethofencarb	87130-20-9	0.05
97.	Clothianidin	210880-92-5	0.01	137.	Difenoconazole	119446-68-3	0.01
98.	Coumaphos	56-72-4	0.05	138.	Diflubenzuron	35367-38-5	0.01
99.	CPMC	3942-54-9	0.02	139.	Diflufenican	83164-33-4	0.05
100.	Cyanazine	21725-46-2	0.05	140.	Dimepiperate	61432-55-1	0.05
101.	Cyanofenphos	13067-93-1	0.01	141.	Dimethametryn	22936-75-0	0.05
102.	Cyanophos	2636-26-2	0.05	142.	Dimethenamid	87674-68-8	0.01
103.	Cyazofamid	120116-88-3	0.01	143.	Dimethipin	55290-64-7	0.05
104.	Cyclosulfamuron	136849-15-5	0.01	144.	Dimethoate	60-51-5	0.01
105.	Cyflufenamid	180409-60-3	0.02	145.	Dimethomorph	110488-70-5	0.01
106.	Cyflumetofen	400882-07-7	0.01	146.	Diniconazole	83657-24-3	0.01
107.	Cyfluthrin	68359-37-5	0.01	147.	Dinitramine	29091-05-2	0.01
108.	Cyhalofop-butyl	122008-85-9	0.01	148.	Dinotefuran	165252-70-0	0.01
109.	Cyhalothrin	91465-08-6	0.01	149.	Diofenolan	63837-33-2	0.05
110.	Cymoxanil	57966-95-7	0.01	150.	Dioxathion	78-34-2	0.02
111.	Cypermethrin	52315-07-8	0.01	151.	Diphenamid	957-51-7	0.01
112.	Cyphenothrin	39515-40-7	0.05	152.	Diphenylamine	122-39-4	0.05
113.	Cyproconazole	94361-06-5	0.01	153.	Disulfoton	298-04-4	0.01
114.	Cyprodinil	121552-61-2	0.01	154.	Ditalimfos	5131-24-8	0.01
115.	o,p'-DDD	53-19-0	0.01	155.	Dithiopyr	97886-45-8	0.01
116.	o,p'-DDE	3424-82-6	0.01	156.	Diuron	330-54-1	0.01
117.	o,p'-DDT	789-02-6	0.01	157.	Dymron	42609-52-9	0.01
118.	p,p'-DDD	72-54-8	0.01	158.	Edifenphos	17109-49-8	0.01
119.	p,p'-DDE	72-55-9	0.01	159.	Emamectin benzoate	155569-91-8	0.02
120.	p,p'-DDT	50-29-3	0.01	160.	α-Endosulfan	959-98-8	0.01

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Appendix

REPORT NO: FA/2017/42165

Date : 2017/04/18



Test items & LOQ List :

unit : ppm(mg/kg)

NO.	Test Item	CAS NO.	LOQ	NO.	Test Item	CAS NO.	LOQ
161.	β-Endosulfan	33213-65-9	0.01	201.	Fipronil-sulfone	120068-36-2	0.05
162.	Endosulfan sulfate	1031-07-8	0.01	202.	Flamprop-methyl	52756-25-9	0.05
163.	Endrin	72-20-8	0.01	203.	Flazasulfuron	104040-78-0	0.01
164.	EPN	2104-64-5	0.01	204.	Flonicamid	158062-67-0	0.01
165.	Epoxiconazole	133855-98-8	0.01	205.	Fluacrypyrim	229977-93-9	0.05
166.	Esfenvalerate	66230-04-4	0.01	206.	Fluazifop-P-butyl	69806-50-4	0.01
167.	Etaconazole	60207-93-4	0.05	207.	Fluazinam	79622-59-6	0.01
168.	Ethalfuralin	55283-68-6	0.05	208.	Flubendiamide	272451-65-7	0.02
169.	Ethiofencarb	29973-13-5	0.02	209.	Flucythrinate	70124-77-5	0.01
170.	Ethion	563-12-2	0.01	210.	Fludioxonil	131341-86-1	0.01
171.	Ethiprole	181587-01-9	0.01	211.	Flufenoxuron	101463-69-8	0.01
172.	Ethirimol	23947-60-6	0.01	212.	Flumethrin	69770-45-2	0.05
173.	Ethoprophos	13194-48-4	0.01	213.	Fluopicolide	239110-15-7	0.01
174.	Ethoxysulfuron	126801-58-9	0.02	214.	Fluoroglycofen-ethyl	77501-90-7	0.05
175.	Etofenprox	80844-07-1	0.01	215.	Fluquinconazole	136426-54-5	0.05
176.	Etoxazole	153233-91-1	0.01	216.	Fluroxypyr-meptyl	81406-37-3	0.05
177.	Etridiazole	2593-15-9	0.05	217.	Flurtamone	96525-23-4	0.02
178.	Etrimfos	38260-54-7	0.01	218.	Flusilazole	85509-19-9	0.01
179.	Famoxadone	131807-57-3	0.01	219.	Flutolanil	66332-96-5	0.01
180.	Fenamiphos	22224-92-6	0.01	220.	Flutriafol	76674-21-0	0.01
181.	Fenarimol	60168-88-9	0.01	221.	Fluvalinate	102851-06-9	0.01
182.	Fenazaquin	120928-09-8	0.01	222.	Folpet	133-07-3	0.04
183.	Fenbuconazole	114369-43-6	0.01	223.	Fonofos	944-22-9	0.01
184.	Fenbutatin-oxide	13356-08-6	0.01	224.	Formetanate	23422-53-9	0.01
185.	Fenchlorphos	299-84-3	0.05	225.	Formothion	2540-82-1	0.01
186.	Fenhexamid	126833-17-8	0.01	226.	Fosthiazate	98886-44-3	0.01
187.	Fenitrothion	122-14-5	0.01	227.	Fthalide	27355-22-2	0.01
188.	Fenobucarb	3766-81-2	0.01	228.	Furametpyr	123572-88-3	0.01
189.	Fenoxanil	115852-48-7	0.05	229.	Furathiocarb	65907-30-4	0.02
190.	Fenothiocarb	62850-32-2	0.01	230.	Halfenprox	111872-58-3	0.01
191.	Fenoxaprop-ethyl	66441-23-4	0.01	231.	Haloxypop-methyl	69806-40-2	0.01
192.	Fenoxycarb	79127-80-3	0.01	232.	Heptachlor	76-44-8	0.01
193.	Fenpropathrin	39515-41-8	0.01	233.	Heptachlor epoxide	1024-57-3	0.01
194.	Fenpropimorph	67564-91-4	0.01	234.	Heptenophos	23560-59-0	0.01
195.	Fenpyroximate	134098-61-6	0.01	235.	Hexachlorobenzene	118-74-1	0.02
196.	Fensulfthion	115-90-2	0.01	236.	Hexaconazole	79983-71-4	0.01
197.	Fenthion	55-38-9	0.01	237.	Hexaflumuron	86479-06-3	0.05
198.	Fenvalerate	51630-58-1	0.01	238.	Hexazinone	51235-04-2	0.01
199.	Ferimzone	89269-64-7	0.02	239.	Hexythiazox	78587-05-0	0.01
200.	Fipronil	120068-37-3	0.001	240.	Imazalil	35554-44-0	0.01

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Appendix

REPORT NO: FA/2017/42165

Date : 2017/04/18



Test items & LOQ List :

unit : ppm(mg/kg)

NO.	Test Item	CAS NO.	LOQ	NO.	Test Item	CAS NO.	LOQ
241.	Imazamethabenz-methyl	81405-85-8	0.05	281.	Metobromuron	3060-89-7	0.01
242.	Imibenconazole	86598-92-7	0.02	282.	Metolachlor	51218-45-2	0.01
243.	Imidacloprid	138261-41-3	0.01	283.	Metolcarb	1129-41-5	0.01
244.	Imidaclothiz	105843-36-5	0.02	284.	Metrafenone	220899-03-6	0.01
245.	Indoxacarb	144171-61-9	0.01	285.	Metribuzin	21087-64-9	0.01
246.	Iprobenfos	26087-47-8	0.01	286.	Mevinphos	7786-34-7	0.01
247.	Iprodione	36734-19-7	0.01	287.	Mirex	2385-85-5	0.01
248.	Isazofos	42509-80-8	0.01	288.	Molinate	2212-67-1	0.01
249.	Isocarbophos	24353-61-5	0.05	289.	Monocrotophos	6923-22-4	0.01
250.	Isofenphos	25311-71-1	0.01	290.	Monolinuron	1746-81-2	0.02
251.	Isoproc carb	2631-40-5	0.01	291.	Myclobutanil	88671-89-0	0.01
252.	Isoprothiolane	50512-35-1	0.01	292.	Napropamide	15299-99-7	0.01
253.	Isouron	55861-78-4	0.01	293.	Nitrothal-isopropyl	10552-74-6	0.05
254.	Isoxathion	18854-01-8	0.01	294.	Norflurazon	27314-13-2	0.01
255.	Jodfenphos	18181-70-9	0.05	295.	Novaluron	116714-46-6	0.01
256.	Kresoxim-methyl	143390-89-0	0.01	296.	Nuarimol	63284-71-9	0.01
257.	Leptophos	21609-90-5	0.05	297.	Octachlorostyrene	29082-74-4	0.05
258.	Lindane	58-89-9	0.01	298.	Omethoate	1113-02-6	0.01
259.	Linuron	330-55-2	0.01	299.	Oryzalin	19044-88-3	0.05
260.	Lufenuron	103055-07-8	0.01	300.	Oxadiazon	19666-30-9	0.01
261.	Malathion	121-75-5	0.01	301.	Oxadixyl	77732-09-3	0.01
262.	Malaaxon	1634-78-2	0.05	302.	Oxamyl	23135-22-0	0.01
263.	Mandipropamid	374726-62-2	0.02	303.	Oxycarboxin	5259-88-1	0.01
264.	Mecarbam	2595-54-2	0.01	304.	Oxychlorane	27304-13-8	0.05
265.	Mefenacet	73250-68-7	0.01	305.	Oxyfluorfen	42874-03-3	0.01
266.	Mepanipyrim	110235-47-7	0.01	306.	Paclobutrazol	76738-62-0	0.01
267.	Mephosfolan	950-10-7	0.01	307.	Paraoxon	311-45-5	0.05
268.	Mepronil	55814-41-0	0.01	308.	Parathion	56-38-2	0.01
269.	Metaflumizon	139968-49-3	0.01	309.	Parathion-methyl	298-00-0	0.01
270.	Metaxyl	57837-19-1	0.01	310.	Penconazole	66246-88-6	0.01
271.	Metazachlor	67129-08-2	0.01	311.	Pencycuron	66063-05-6	0.01
272.	Metconazole	125116-23-6	0.01	312.	Pendimethalin	40487-42-1	0.01
273.	Methacrifos	62610-77-9	0.01	313.	Penoxsulam	219714-96-2	0.01
274.	Methamidophos	10265-92-6	0.01	314.	Pentachloroaniline	527-20-8	0.01
275.	Methidathion	950-37-8	0.01	315.	Pentachloroanisole	1825-21-4	0.05
276.	Methiocarb	2032-65-7	0.01	316.	Pentachlorobenzene	608-93-5	0.05
277.	Methomyl	16752-77-5	0.01	317.	Permethrin	52645-53-1	0.01
278.	Methoxychlor	72-43-5	0.05	318.	Phenothrin	26002-80-2	0.05
279.	Methoxyfenozide	161050-58-4	0.01	319.	Phenthoate	2597-03-7	0.01
280.	Methyl pentachlorophenyl sulfide	1825-19-0	0.01	320.	Phorate	298-02-2	0.01

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Appendix

REPORT NO: FA/2017/42165

Date : 2017/04/18



Test items & LOQ List :

unit : ppm(mg/kg)

NO.	Test Item	CAS NO.	LOQ	NO.	Test Item	CAS NO.	LOQ
321.	Phosalone	2310-17-0	0.01	361.	Pyrifenox	88283-41-4	0.01
322.	Phosmet	732-11-6	0.01	362.	Pyrimethanil	53112-28-0	0.02
323.	Phosphamidon	13171-21-6	0.01	363.	Pyrimidifen	105779-78-0	0.01
324.	Phoxim	14816-18-3	0.01	364.	Pyriproxyfen	95737-68-1	0.01
325.	Picolinafen	137641-05-5	0.05	365.	Pyroquilon	57369-32-1	0.01
326.	Piperonyl butoxide	51-03-6	0.02	366.	Quinalphos	13593-03-8	0.01
327.	Piperophos	24151-93-7	0.05	367.	Quinoxifen	124495-18-7	0.01
328.	Pirimicarb	23103-98-2	0.01	368.	Quintozene(PCNB)	82-68-8	0.01
329.	Pirimiphos-ethyl	23505-41-1	0.01	369.	Quizalofop-ethyl	76578-14-8	0.01
330.	Pirimiphos-methyl	29232-93-7	0.01	370.	Rotenone	83-79-4	0.02
331.	Prallethrin	23031-36-9	0.02	371.	Salithion	3811-49-2	0.01
332.	Pretilachlor	51218-49-6	0.01	372.	Sethoxydim	74051-80-2	0.02
333.	Probenazole	27605-76-1	0.02	373.	Silafiuofen	105024-66-6	0.01
334.	Prochloraz	67747-09-5	0.01	374.	Simazine	122-34-9	0.01
335.	Procymidone	32809-16-8	0.01	375.	Simeconazole	149508-90-7	0.05
336.	Profenophos	41198-08-7	0.01	376.	Spinetoram J	187166-40-1	0.01
337.	Promecarb	2631-37-0	0.01	377.	Spinetoram L	187166-40-1	0.01
338.	Prometryn	7287-19-6	0.01	378.	Spinosad A	168316-95-8	0.01
339.	Propachlor	1918-16-7	0.05	379.	Spinosad D	168316-95-8	0.01
340.	Propamocarb hydrochloride	25606-41-1	0.01	380.	Spirodiclofen	148477-71-8	0.01
341.	Propanil	709-98-8	0.01	381.	Spirotetramat	203313-25-1	0.01
342.	Propaphos	7292-16-2	0.01	382.	Tebuconazole	107534-96-3	0.01
343.	Propargite	2312-35-8	0.01	383.	Tebufenozide	112410-23-8	0.01
344.	Propazine	139-40-2	0.01	384.	Tebufenpyrad	119168-77-3	0.01
345.	Propham	122-42-9	0.02	385.	Tebuthiuron	34014-18-1	0.05
346.	Propiconazole	60207-90-1	0.01	386.	Tecnazene	117-18-0	0.05
347.	Propoxur	114-26-1	0.01	387.	Teflubenzuron	83121-18-0	0.01
348.	Propyzamide	23950-58-5	0.05	388.	Tefluthrin	79538-32-2	0.05
349.	Proquinazid	189278-12-4	0.02	389.	Tepraloxymid	149979-41-9	0.01
350.	Prosulfocarb	52888-80-9	0.02	390.	Terbufos	13071-79-9	0.01
351.	Prothiofos	34643-46-4	0.01	391.	Terbutryn	886-50-0	0.05
352.	Pymetrozine	123312-89-0	0.01	392.	Tetrachlorvinphos	22248-79-9	0.05
353.	Pyraclofos	77458-01-6	0.01	393.	Tetraconazole	112281-77-3	0.01
354.	Pyraclostrobin	175013-18-0	0.01	394.	Tetradifon	116-29-0	0.01
355.	Pyraflufen-ethyl	129630-19-9	0.05	395.	Tetramethrin	7696-12-0	0.01
356.	Pyrazophos	13457-18-6	0.01	396.	Thenylchlor	96491-05-3	0.01
357.	Pyrazosulfuron-ethyl	93697-74-6	0.02	397.	Thiabendazole	148-79-8	0.01
358.	Pyridaben	96489-71-3	0.01	398.	Thiacloprid	111988-49-9	0.01
359.	Pyridaphenthion	119-12-0	0.01	399.	Thiamethoxam	153719-23-4	0.01
360.	Pyridate	55512-33-9	0.01	400.	Thifluzamide	130000-40-7	0.01

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Appendix

REPORT NO: FA/2017/42165

Date : 2017/04/18

Test items & LOQ List :

unit : ppm(mg/kg)

NO.	Test Item	CAS NO.	LOQ	NO.	Test Item	CAS NO.	LOQ
401.	Thiobencarb	28249-77-6	0.01	414.	Tridemorph	81412-43-3	0.05
402.	Thiodicarb	59669-26-0	0.01	415.	Tridiphane	58138-08-2	0.01
403.	Thiometon	640-15-3	0.05	416.	Trifloxystrobin	141517-21-7	0.01
404.	Tolclofos-methyl	57018-04-9	0.01	417.	Triflumizole	99387-89-0	0.01
405.	Tolfenpyrad	129558-76-5	0.01	418.	Trifluralin	1582-09-8	0.01
406.	Tolyfluanid	731-27-1	0.02	419.	Triforine	26644-46-2	0.01
407.	Triadimefon	43121-43-3	0.01	420.	Trinexapac-ethyl	95266-40-3	0.05
408.	Triadimenol	55219-65-3	0.01	421.	Uniconazole	83657-17-4	0.01
409.	Tri-allate	2303-17-5	0.05	422.	Vamidothion	2275-23-2	0.01
410.	Triazophos	24017-47-8	0.01	423.	Vinclozolin	50471-44-8	0.01
411.	Tribufos	78-48-8	0.05	424.	XMC	2655-14-3	0.01
412.	Trichlorfon	52-68-6	0.01	425.	Xylylcarb	2425-10-7	0.01
413.	Tricyclazole	41814-78-2	0.01	426.	Zoxamide	156052-68-5	0.01

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

CHARSIRE Biotechnology Corp.
 4F-1, No. 13, Nanke 2nd Rd., Xinshi Dist., Tainan City, Taiwan

REPORT NO : FA/2017/42165
 Date : 2017/04/18



Sample Photo

FA/2017/42165



FA/2017/42165



This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.